Travere Therapeutics, Inc.
TVTX
Classement en actions
#3483
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Prix de l'action
$52.44
Capitalisation boursière
$4.94B
Changement (1 jour)
3.87%
Changement (1 an)
88.03%
Pays
US
Échange Travere Therapeutics, Inc. (TVTX)
Catégorie
Healthcare
Bénéfices pour Travere Therapeutics, Inc. (TVTX)
Bénéfices en Jun 2026 TTM : $-67.07M
Selon les derniers rapports financiers de Travere Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de $-67.07M. En 2023, l'entreprise a réalisé un bénéfice de $-376.11M, une diminution par rapport à celui de 2022 qui était de $-331.16M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Travere Therapeutics, Inc. de 2009 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-67.07M | -79.07% |
| 2024 | $-320.51M | -14.78% |
| 2023 | $-376.11M | 13.58% |
| 2022 | $-331.16M | 52.69% |
| 2021 | $-216.88M | 14.88% |
| 2020 | $-188.79M | 28.91% |
| 2019 | $-146.45M | 43.76% |
| 2018 | $-101.87M | 74.54% |
| 2017 | $-58.36M | 1.36% |
| 2016 | $-57.58M | -154.60% |
| 2015 | $105.47M | -193.01% |
| 2014 | $-113.40M | 236.02% |
| 2013 | $-33.75M | 11.22% |
| 2012 | $-30.34M | 166,022.06% |
| 2009 | $-18.27K | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
